On October 1, 2026, Edwards Lifesciences announced FDA approval of the AUTUS Size-Adjustable Valve for children with congenital heart defects requiring pulmonary valve replacement. According to the company, it is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy.
Why the timing of valve replacement in children with congenital heart disease has been so difficult
The right timing for valve replacement in children with congenital heart disease is difficult, explained Michelle Tarver, director of the FDA's Center for Devices and Radiological Health. Waiting too long risks harming the child; intervening too early can require multiple open-heart surgeries during growth. Treatment of congenital heart defects can improve blood flow, but patients can also develop significant pulmonary valve insufficiency, weakening or enlarging the right ventricle and increasing the need for valve replacement as the child grows. Conventional valve leaflets made from animal tissue harden and deteriorate faster in children, often requiring earlier repeat surgeries.
How the valve works and what the study shows
This is a prospective, single-arm, multicenter study without a comparison group involving children ages 18 months to 16 years. According to FDA information reported by MassDevice, AUTUS can initially be implanted at only 13 millimeters in diameter, an appropriate size for a toddler or preschool child. Over time, it can be expanded via a minimally invasive catheter procedure using a balloon to up to 22 millimeters, comparable to a pulmonary valve for adults. The valve leaflets are made from polymer material rather than animal tissue, making AUTUS the first artificially designed heart valve approved in the US with leaflets of this material. The approval is based on this study with 62 pediatric patients at 12 US sites. At six-month follow-up, the first 60 patients showed acceptable hemodynamic function and at most mild valve insufficiency. All participants had successful procedures, with no deaths, treatment-requiring blood clots, strokes, or other clot-related complications. The primary safety endpoint covers 30 days; information on valve function and repeat AUTUS procedures covers six months.
What the uncertain hope rests on
Jennifer Romano, cardiac surgeon at C.S. Mott Children's Hospital, called the valve a "game changer" in September at the first AUTUS implantation within the Continued-Access study and believed it might be possible to give a child a valve that could last a lifetime. Study investigator Emile Bacha also sees in AUTUS a new opportunity for long-term care planning for children who otherwise face multiple surgeries. Edwards discloses that Bacha has received travel and accommodation reimbursement from the company for educational activities. The company explicitly marks expected benefits such as fewer open-heart surgeries as forward-looking, uncertain statements. Patients will continue to be monitored for 10 years.
In context: a building block in the existing toolkit
Edwards positions the approval within its existing portfolio for congenital heart disease, which also includes SAPIEN 3, the Alterra Adaptive Prestent, and pediatric atrioseptostomy catheters. Earlier artificial pulmonary valves could be implanted long ago but typically required a series of surgeries to replace them with larger ones as the child grew. AUTUS is intended to break precisely this cycle: FDA Director Tarver explains that the valve gives physicians the option to enter the operating room far less frequently, potentially improving the quality of life for children and families.
The study's primary completion was noted for August 24, 2026, with estimated total completion listed as February 5, 2036. The study calls for at least one additional year of follow-up after expansion. According to SPARK program director Kolaleh Eskandanian, a regulatory gap exists in expanding the product label to additional pediatric age groups; she calls for testing methods, open virtual patient cohorts, and a pre-agreed plan for product labeling.